These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29854415)

  • 21. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model.
    Turner AP; Kivlahan DR; Sloan AP; Haselkorn JK
    Mult Scler; 2007 Nov; 13(9):1146-52. PubMed ID: 17967842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
    Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
    Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
    Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
    Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
    Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).
    Patti F; Chisari CG; D'Amico E; Annovazzi P; Banfi P; Bergamaschi R; Clerici R; Conti MZ; Cortese A; Fantozzi R; Fischetti M; Frigo M; Gatto M; Immovilli P; Leoni S; Malucchi S; Maniscalco G; Marfia GA; Paolicelli D; Perini P; Serrati C; Sola P; Totaro R; Turano G; Valentino P; Zaffaroni M; Zuliani C; Centonze D
    Mult Scler Relat Disord; 2020 Jul; 42():102124. PubMed ID: 32353755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis.
    Ožura A; Kovač L; Sega S
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S6-11. PubMed ID: 24321157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
    Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
    PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.